ConductScience.org, home

Paper40717455

Network Meta-Analysis: Comparative Efficacy of Biologics and Small Molecules in the Induction and Maintenance of Remission in Crohn's Disease.

Shehab M and 8 others. Aliment Pharmacol Ther, 2025. Cited by 12 papers, by iCite.

Cite this record

ConductScience Library. Network Meta-Analysis: Comparative Efficacy of Biologics and Small Molecules in the Induction and Maintenance of Remission in Crohn's Disease. Papers, record 40717455. Release papers-2026-11-12-0.1.0, 12 Nov 2026. https://conductscience.org/library/papers/40717455

Download JSON
Sources
11 sources
Release
papers-2026-11-12-0.1.0

Paper

PubMed's record of the paper, with iCite's citation figures. No abstract is shown.

Title
Network Meta-Analysis: Comparative Efficacy of Biologics and Small Molecules in the Induction and Maintenance of Remission in Crohn's Disease.
PubMed
Journal
Aliment Pharmacol Ther
PubMed
Year
2025
PubMed
Publication types
Comparative Study, Journal Article, Network Meta-Analysis, Systematic Review
PubMed
Citations, by iCite
12
iCite
Relative citation ratio, by iCite
3.27, provisional
iCite
Revised in PubMed
2025-09-05
PubMed

Authors9

The authors in the order PubMed's record lists them, with the ORCID iDs it states.

OrderAuthorForenameKindORCID iD
1Shehab MMohammadhttps://orcid.org/0000-0003-2084-3956
2Alrashed FFatema
3Alrashidi AAbdulrahman
4Hassan AAmro
5Ma CChristopherhttps://orcid.org/0000-0002-4698-9948
6Narula NNeerajhttps://orcid.org/0000-0002-1536-8436
7Jairat VVipulhttps://orcid.org/0000-0002-1092-0033
8Regueiro MMiguelhttps://orcid.org/0000-0002-7681-8111
9Bessissow TTalat

Source PubMed

Download CSV of authors

Topics11

NLM's MeSH indexing of the paper, its major topics first.

MeSH termMajor
Biological ProductsMajor topic
Crohn DiseaseMajor topic
Humans
Adalimumab
Antibodies, Monoclonal, Humanized
Drug Therapy, Combination
Infliximab
Maintenance Chemotherapy
Randomized Controlled Trials as Topic
Remission Induction
Treatment Outcome

Source PubMed

Download CSV of topics

Cited by9

The papers in our copy of PubMed whose reference list names this one, newest first. iCite, which reads more sources, counts 12 citations.

PMIDTitleJournalYearIn PapersSource
42928005[KASID Guidelines for the Medical Treatment of Crohn's Disease: 2026].Korean J Gastroenterol2026https://conductscience.org/library/papers/42928005PubMed
42835383Targeting IL-23p19 in Inflammatory Bowel Disease: The Road Ahead.J Inflamm Res2026https://conductscience.org/library/papers/42835383PubMed
42381756Real-world effectiveness of guselkumab for induction of remission in Crohn's disease: a prospective multicenter cohort study with propensity score-matched comparison to risankizumab.Crohns Colitis 3602026https://conductscience.org/library/papers/42381756PubMed
42376682Considerations in reviewing network meta-analyses of heterogeneous clinical trial designs: a methodological review in Crohn's disease and ulcerative colitis.Crohns Colitis 3602026https://conductscience.org/library/papers/42376682PubMed
42362204Anti-TNF immunogenicity in a Middle Eastern inflammatory bowel disease cohort: prevalence, predictors and context-specific drug level thresholds.BMJ Open Gastroenterol2026https://conductscience.org/library/papers/42362204PubMed
42241358STRIDE-II treatment target achievement in inflammatory bowel disease: a cross-sectional study from a tertiary IBD centre in the United Arab Emirates.Saudi J Gastroenterol2026https://conductscience.org/library/papers/42241358PubMed
42240958Combining Guselkumab with Upadacitinib Is Safe and Effective in the Treatment of Medically Complex Inflammatory Bowel Disease.Dig Dis Sci2026https://conductscience.org/library/papers/42240958PubMed
41745409Interleukin-23p19 Inhibitors in Inflammatory Bowel Disease: From Current Insights to Future Directions.J Pers Med2026https://conductscience.org/library/papers/41745409PubMed
41595725Optimizing Drug Positioning in IBD: Clinical Predictors, Biomarkers, and Practical Approaches to Personalized Therapy.Biomedicines2026https://conductscience.org/library/papers/41595725PubMed

Download CSV of cited by

Genes1

The genes the Gene search release ties to the paper: Swiss-Prot's references first, then PubTator's text mining.

GeneNCBI Gene IDLinked byIn Genes
IL23A51561PubTator's text mininghttps://conductscience.org/library/genes/51561

Source NCBI Gene

Download CSV of genes

Data dates

The date of each source this release read.

PubMed
2026-11-06
PubMed
iCite
2026-11-05
iCite
PMC's ID file
2026-11-05
PMC's ID file
NIH RePORTER's grant and paper links
2026-11-01
NIH RePORTER's grant and paper links
Trials
2026-11-12
Gene search
2026-11-11
Pipelines
2026-09-18

None in this release

  • Grants
  • Trials
  • Comments and corrections
  • References
  • Drugs
  • Data

Sources 11

  • ChEMBL, through Open TargetsCC BY-SA 3.0
  • ClinicalTrials.govNo license stated
  • HGNCCC0
  • iCiteCC BY 4.0
  • NCBI GenePublic domain (US government)
  • NIH RePORTER's grant and paper linksPublic domain
  • Open TargetsCC0 1.0
  • PMC's ID filePublic domain (US government)
  • PubMedNLM's terms
  • PubTator 3Public domain
  • UniProtCC BY 4.0
Each source's terms
  • ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
  • ClinicalTrials.govnone stated
  • HGNCCC0: https://www.genenames.org/about/license/
  • iCiteCC BY 4.0
  • NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
  • NIH RePORTER's grant and paper linksPublic domain (NIH RePORTER)
  • Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
  • PMC's ID fileNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
  • PubMedNLM's terms
  • PubTator 3Public domain
  • UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.

For software

Read this paper from software.

The record and each of its lists are JSON, twenty rows a page. No key.

GET https://conductscience.org/api/papers/v1/40717455

GET https://conductscience.org/api/papers/v1/40717455/authors